Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Temsirolimus in Recurrent Glioblastoma
NCT00329719Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2006
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sorafenib and temsirolimus in glioblastoma (GBM) and Gliosarcoma (GS), sponsored by National Cancer Institute. Started Mar 2006; status: completed.
02
Drugs
sorafenibtemsirolimus
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00329719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00329719.